Metallothionein expression in human neoplasia

Histopathology - Tập 45 Số 2 - Trang 103-118 - 2004
Stamatis Theocharis1, Alexandra Margeli1, Jerzy Klijanienko1, Gregory Kouraklis2
1Department of Tumour Biology, Institut Curie, Paris, France, Department of Clinical Biochemistry, ‘Aghia Sophia’ Children's Hospital
22nd Department of Propedeutic Surgery, School of Medicine, University of Athens, Athens, Greece

Tóm tắt

The metallothionein family is a class of low‐molecular‐weight, cysteine‐rich proteins with high affinity for metal ions. Four major isoforms (metallothionein‐1, ‐2, ‐3, and ‐4) have been identified in mammals, involved in many pathophysiological processes, including metal ion homeostasis and detoxification, protection against oxidative damage, cell proliferation and apoptosis, drug and radiotherapy resistance and several aspects of the carcinogenic process. In the present review we examine the expression of metallothionein in different human tumours and its correlation with histopathological variables, tumour cell proliferation or apoptosis, resistance to radiation or chemotherapy, patient survival and prognosis. A variable profile of metallothionein and its isoforms' expression has been observed in different cancer types. Although metallothionein expression has been implicated in carcinogenic evolution, its use as a marker of tumour differentiation, cell proliferation and prognosis predictor remains unclear. Detailed studies focused on the expression of metallothionein isoforms and isotypes in different tumour types could elucidate the role of this group of proteins in the carcinogenic process, delineating its possible clinical significance for the management of patients.

Từ khóa


Tài liệu tham khảo

10.1021/ja01574a064

10.1016/0896-6273(91)90272-2

10.1074/jbc.270.36.20898

10.1073/pnas.89.14.6333

10.1021/bi00189a029

10.1016/0162-0134(94)80023-5

10.3109/03602539709037585

10.1073/pnas.95.7.3483

10.1073/pnas.88.22.9984

10.1016/0014-5793(91)80175-3

10.1073/pnas.96.5.1936

10.1096/fj.00-0641fje

10.1016/S0009-2797(97)00165-8

10.1016/S0162-0134(96)00201-2

10.1016/S0162-0134(96)00197-3

10.1016/S0024-3205(01)01294-2

10.1177/172460080301800302

10.1046/j.1365-2559.1997.2140848.x

10.1126/science.8023157

10.1016/0167-4838(94)90197-X

Hainaut P, 1993, A structural role of metal ions in the ‘wild‐type’ conformation of the tumor suppressor protein p53, Cancer Res., 53, 1739

10.1101/gad.7.12b.2556

10.1128/MCB.15.7.3892

10.1038/sj.onc.1203907

Abdel‐Mageed A, 1997, Antisense down‐regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells, Cancer Gene Ther., 4, 199

10.1124/mol.52.2.195

10.1006/taap.1994.1083

10.1042/0264-6021:3550473

Tsangaris GT, 1998, Metallothionein expression prevents apoptosis: a study with antisense phosphorothioate oligodeoxynucleotides in a human T cell line, Anticancer Res., 18, 2423

10.1093/toxsci/kfg095

10.1002/(SICI)1096-9896(199601)178:1<84::AID-PATH430>3.0.CO;2-W

10.1016/S0300-483X(98)00150-4

10.1016/S0959-8049(97)00216-5

10.3109/00016489709124029

Muramatsu Y, 2000, Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses, Anticancer Res., 20, 257

10.1159/000227714

10.1046/j.1365-2168.2002.02057.x

Jayasura A, 2000, Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma, Br. J. Cancer, 82, 1198, 10.1054/bjoc.1999.1063

10.1093/carcin/21.10.1809

10.1016/S0304-3835(00)00414-6

10.1016/S0344-0338(99)80102-2

Tuccari G, 2000, Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa, Histol. Histopathol., 15, 1035

Theocharis S, 2001, Metallothionein expression in human gastric cancer, J. Eur. Surg. Res., 33, 137

Ebert MP, 2000, Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer, Cancer Res., 60, 1995

10.1159/000227725

Janssen AM, 2002, Prognostic significance of metallothionein in human gastrointestinal cancer, Clin. Cancer Res., 8, 1889

10.1111/j.1365-2559.1996.tb01418.x

Theocharis S, 1997, Immunohistochemical expression of metallothionein in colorectal adenomatous polyps, Gastroenterology, 112, A668

10.1007/BF00197552

10.1002/(SICI)1096-9896(199802)184:2<144::AID-PATH998>3.0.CO;2-J

10.1007/s00268-002-6266-z

10.1002/1096-9896(2000)9999:9999<::AID-PATH712>3.0.CO;2-Z

10.1111/j.1699-0463.1999.tb01575.x

10.1159/000055368

10.1007/BF02236987

10.1002/cncr.10780

10.1136/jcp.52.12.876

10.1002/(SICI)1097-0215(19960703)67:1<20::AID-IJC5>3.0.CO;2-1

Tanimoto K, 1998, Immunohistochemical localization of metallothionein in hepatocellular carcinoma: preferential expression in non‐cancerous cirrhotic nodules, Oncol. Rep., 5, 805

10.1046/j.1365-2559.1998.00348.x

Cai L, 1998, Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China, Anticancer Res., 18, 4667

10.1016/S0168-8278(00)80277-9

Hall KS, 1991, Induction of in vitro resistance to 4′‐epidoxorubicin and cis‐dichlorodiammineplatinum in hepatoma cells, Anticancer Res., 11, 817

10.1046/j.1365-2559.1998.00474.x

10.1007/BF01220802

10.1046/j.1440-1827.2002.01368.x

10.1038/modpathol.3880064

10.1016/S0304-3835(96)04471-0

10.1046/j.1365-2559.2002.01325.x

10.1093/carcin/16.9.2129

10.1002/1097-0142(20010815)92:4<836::AID-CNCR1390>3.0.CO;2-K

10.1016/0304-3835(93)90196-G

10.1038/sj.bjc.6600463

Matsumoto Y, 1997, Enhanced expression of metallothionein in human non‐small‐cell lung carcinomas following chemotherapy, Anticancer Res., 17, 3777

10.1615/CritRevOncog.v7.i3-4.50

10.1016/S0093-7754(01)90058-2

Volm M, 2000, Cellular predictive factors for the drug response of lung cancer, Anticancer Res., 20, 3449

10.1053/rmed.2001.1108

10.1016/S0090-4295(98)00323-9

10.1046/j.1464-410x.1998.00506.x

10.1016/S0022-5347(05)66399-9

Mitropoulos D, 2001, Prognostic significance of metallothionein expression in renal cell carcinoma, Eur. Urol., 39, 187

10.1093/oxfordjournals.jbchem.a002852

10.1016/S0304-3835(00)00534-6

10.1159/000045425

Somji S, 2001, Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT‐1X mRNA in bladder cancer, Cancer Detect. Prev., 25, 62

10.1016/S0022-5347(17)38155-7

Katoh S, 1994, Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract, J. Urol., 152, 1267, 10.1016/S0022-5347(17)32565-X

Ioachim EE, 2001, Localization of metallothionein inurothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA‐DR antigen, p53, and proliferation indices, Anticancer Res., 21, 1757

Sens MA, 2000, Metallothionein isoform 3 as a potent biomarker for human bladder cancer, Environ. Health Perspect., 108, 413, 10.1289/ehp.00108413

10.1111/j.1442-2042.1994.tb00022.x

Wood DP, 1993, Metallothionein expression in bladder cancer exposed to cisplatin, Mod. Pathol., 6, 33

10.1016/S0022-5347(17)31656-7

10.1007/s002400050103

Siu LL, 1998, The prognostic role of p53, metallothionein, P‐glycoprotein, and MIB‐1 in muscle‐invasive urothelial transitional cell carcinoma, Clin. Cancer Res., 4, 559

Satoh M, 1994, Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis, Cancer Res., 54, 5255

10.1007/BF01614773

10.1007/s004410000310

10.1007/BF00665963

10.1007/BF01607167

10.1159/000227546

10.1038/bjc.1995.443

10.1111/j.1699-0463.1995.tb01107.x

10.1007/s004280050046

Zhang R, 2000, Expression of metallothionein in invasive ductal breast cancer in relation to prognosis, J. Environ. Pathol. Toxicol. Oncol., 19, 95

10.1023/A:1010658907462

10.1016/S0344-0338(11)80746-6

10.1016/S0344-0338(00)80027-8

10.1016/S1357-2725(00)00024-8

10.1093/carcin/23.1.81

10.1054/bjoc.2000.1276

10.1016/S0002-9440(10)61668-9

Ioachim E, 1999, Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin‐1, CD44, extracellular matrix components, p53, Rb, C‐erbB‐2, EGFR, steroid receptor content and proliferation, Anticancer Res., 19, 2133

10.1517/14728222.6.3.375

10.1038/bjc.1991.160

10.1046/j.1525-1438.2002.01081.x

10.1046/j.1525-1438.1994.04040241.x

10.1097/00004347-199601000-00009

10.1097/00004347-199910000-00009

10.1002/(SICI)1096-9896(199909)189:1<60::AID-PATH387>3.0.CO;2-J

Hengstel JG, 2001, Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis, Int. J. Cancer, 95, 121, 10.1002/1097-0215(20010320)95:2<121::AID-IJC1021>3.0.CO;2-N

10.1007/PL00008477

10.1007/BF00254568

10.1111/j.1349-7006.1997.tb00368.x

10.1002/1096-9896(2000)9999:9999<::AID-PATH616>3.0.CO;2-Q

10.1046/j.1365-2559.1999.00579.x

10.1097/00004347-199801000-00006

Theocharis S, 1999, Expression of metallothionein in malignant transformation of cervical neoplasia: an immunohistochemical study, Virchows Arch., 435, 234

Raleigh JA, 2000, A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas, Clin. Cancer Res., 6, 855

10.1002/pros.2990190104

Moussa M, 1997, Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum levels of prostate‐specific antigen, Clin. Invest. Med., 20, 371

10.1002/pros.10097

Kondo Y, 1995, Metallothionein localization and cisplatin resistance in human hormone‐independent prostatic tumor cell lines, Cancer Res., 55, 474

10.1002/1097-0142(19931115)72:10<3029::AID-CNCR2820721027>3.0.CO;2-6

Koropatnick J, 1995, Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line, J. Pharmacol. Exp. Ther, 275, 1681

10.1002/(SICI)1097-0215(20000315)85:6<777::AID-IJC6>3.0.CO;2-D

10.1007/s004320050130

10.1016/0959-8049(96)00033-0

10.1007/BF00718648

Tews DS, 2001, Intrinsic expression of drug resistance‐associated factors in meningiomas, Appl. Immunohistochem. Mol. Morphol., 9, 242, 10.1097/00129039-200109000-00008

10.1007/s004010050755

10.1023/A:1006491405010

10.1002/(SICI)1097-0142(19981201)83:11<2361::AID-CNCR16>3.0.CO;2-N

10.1023/A:1006369829576

Yasuno T, 1999, Establishment and characterization of a cisplatin‐resistant human neuroblastoma cell line, Anticancer Res., 19, 4049

10.1007/s00428-003-0815-1

10.1097/00022744-200212000-00012

10.1038/bjc.1998.573

10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J

Zhang B, 1998, Metallothionein deficiency promotes mouse skin carcinogenesis induced by 7,12‐dimethylbenz[a]anthracene, Cancer Res., 58, 4044

10.1111/j.1751-1097.1997.tb08603.x

10.1002/mc.2940020208

10.1046/j.1365-2133.1997.d01-1138.x

Aroni K, 1998, Immunohistochemical expression of metallothionein in different dermal lesions, Arch. Anat. Cytol. Path. Clin. Exp. Pathol., 46, 344

10.1111/j.1365-2559.1993.tb01198.x

Goldmann T, 1998, Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics, J. Exp. Clin. Cancer Res., 17, 483

10.1097/00000372-200102000-00005

10.1007/s004030000202

10.1038/313709a0

10.1016/0888-7543(90)90459-8

10.1007/BF01695690

Sauerbrey A, 1998, Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL), Anticancer Res., 18, 1231

Tsangaris GT, 2000, Metallothionein expression prevents apoptosis. II: evaluation of the role of metallothionein expression on the chemotherapy‐induced apoptosis during the treatment of acute leukemia, Anticancer Res., 20, 4407

10.1177/112067210001000407

10.1046/j.1365-2559.1997.d01-603.x

Thông tin
Thông tin xuất bản

Histopathology

Tập 45 Số 2

103-118

Thông tin tác giả